KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares OutstandingShares Repurchased
Ratios

Halozyme Therapeutics (HALO) EBIAT: 2009-2025

Historic EBIAT for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $175.2 million.

  • Halozyme Therapeutics' EBIAT rose 27.89% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 51.73%. This contributed to the annual value of $444.1 million for FY2024, which is 57.71% up from last year.
  • Halozyme Therapeutics' EBIAT amounted to $175.2 million in Q3 2025, which was up 6.09% from $165.2 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' EBIAT ranged from a high of $216.6 million in Q3 2021 and a low of $22.7 million during Q2 2022.
  • Over the past 3 years, Halozyme Therapeutics' median EBIAT value was $93.2 million (recorded in 2024), while the average stood at $107.7 million.
  • Its EBIAT has fluctuated over the past 5 years, first surged by 557.07% in 2021, then crashed by 75.20% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' EBIAT (Quarterly) stood at $66.8 million in 2021, then declined by 13.58% to $57.7 million in 2022, then spiked by 47.98% to $85.4 million in 2023, then spiked by 60.46% to $137.0 million in 2024, then rose by 27.89% to $175.2 million in 2025.
  • Its EBIAT was $175.2 million in Q3 2025, compared to $165.2 million in Q2 2025 and $118.1 million in Q1 2025.